Recent News

Novel CRISPR Approach May Uncover Regulators of Lung Cancer Development

Newly Identified HER2 Mutations in Non–Small Cell Lung Cancer Focus on Exons 18 and 19

IMpower150 Mutational Subgroup Analysis of Chemoimmunotherapy for KRAS-Mutated Lung Cancer

Can MCT4 Blockade Counter Resistance to Immunotherapy in LKB1-Mutant Lung Cancer?

Polymorphisms in Immune Checkpoint Proteins and Response to Immunotherapy

Preclinical Rationale for Combining KRAS and MCL1 Inhibitors in KRAS-Mutant Lung Cancer

AACR 2022: Overall Survival Update With Sotorasib in KRAS-Mutated Lung Cancer

AACR 2022: Nivolumab Plus Chemotherapy for Resectable Lung Cancer in Phase III CheckMate 816 Trial

AACR 2022: Neoadjuvant Durvalumab Alone or in Combination for Early-Stage Lung Cancer

Fam-Trastuzumab Deruxtecan-nxki Granted Priority Review in HER2-Mutant NSCLC

Update From LIBRETTO-001: Selpercatinib in RET Fusion–Positive NSCLC

AACR 2022: Circulating Tumor DNA–Based Monitoring After Surgery for NSCLC

AACR 2022: Could Estrogen Derivatives Be Linked to Lung Cancer in Never-Smokers?

AACR 2022: Can Somatic Mutations and Ancestry Provide Risk Clues in Latin American Patients?

Targeting HER2 Mutations in NSCLC With Triplet Therapy

Does Adding Radiotherapy to Immunotherapy Improve Outcomes in Metastatic NSCLC?

5-Year PACIFIC Follow-Up: Durvalumab in Stage III NSCLC

ELCC 2022: How Prevalent Is Biomarker Testing in Patients With Advanced Lung Cancer?

Analyzing the Racial Disparities in Lung Cancer Screening Eligibility: Focus on 2021 USPSTF Criteria

FDA Brief: Companion Diagnostic Approved for NSCLC With EGFR Mutations

CHOICE-01 Trial: Toripalimab Plus Chemotherapy in Advanced NSCLC

Third-Generation EGFR TKI Abivertinib: Focus of Early-Stage Research in Lung Cancer

Can Routine Imaging for Lung Cancer Radiotherapy Planning Predict Cardiac Mortality?

Neoadjuvant Nivolumab and Platinum-Doublet Chemotherapy Approved for Early-Stage NSCLC

Consolidation Therapy With Sugemalimab in Stage III Non–Small-Cell Lung Cancer

FDA Brief: Priority Review for Nivolumab Plus Chemotherapy as Neoadjuvant Treatment in Lung Cancer

Mobocertinib for EGFR Exon 20 Insertion–Positive Metastatic NSCLC

Role of Bupivacaine in Pain Management After Lobectomy for Early-Stage Lung Cancer

FDA Brief: New Drug Application Accepted for Adagrasib in KRAS G12C–Mutated NSCLC

Lung ART Trial: Postoperative Radiotherapy Under Study in Stage IIIAN2 NSCLC

CMS to Expand Eligibility Criteria for Low-Dose CT Screening for Lung Cancer

STS 2022: Surgical Wedge Resection Versus Stereotactic Radiation Therapy for in Situ NSCLC

STS 2022: Radiomic Approach to Predicting Histologic Subtype of Early-Stage Lung Adenocarcinoma

STS 2022: Does High-Intensity Surveillance After Surgery Improve Outcomes in Stage I NSCLC?

STS 2022: Surgical Approaches to Lobectomy for NSCLC: Lymph Node Upstaging and Overall Survival

Use of Patritumab Deruxtecan in EGFR Inhibitor–Resistant NSCLC

Use of Blood-Based Proteomic Test to Predict Outcomes With Immunotherapy for NSCLC

FDA Brief: Cemiplimab-rwlc Accepted for Review in First-Line Combination Therapy for Advanced Lung Cancer

Potential Correlation Between Stage Shift and Survival Among Patients With NSCLC

ZENITH20 Trial: Poziotinib in NSCLC After Prior Therapies

Global Study of Sequential Afatinib and Osimertinib in EGFR Mutation–Positive NSCLC

FDA Brief: Novel EGFR Inhibitor Granted Breakthrough Therapy Designation in Lung Cancer

Anti-TIGIT Monoclonal Antibody Plus Pembrolizumab Focus of Phase II Study in NSCLC

Biomarker-Directed Analysis of First-Line Pembrolizumab-Based Therapies in NSCLC

Tumor Biopsy Analysis of Anticancer Vaccine–Treated Patients With Advanced NSCLC

Chemoradiation Plus Pembrolizumab for Locally Advanced NSCLC

Survival Rates for Lung Cancer: Increasing but Still Lower in People of Color

SITC 2021: Early-Phase Study Results of LN-145 Monotherapy in NSCLC

Stereotactic Body Radiation Therapy and Primary Tumor Control in NSCLC

SITC 2021: Prevalence of KRAS mutations in Advanced Nonsquamous NSCLC

SITC 2021: Immunomodulatory Effects of Neoadjuvant Nivolumab and Chemotherapy in NSCLC

How Does Ensartinib Compare With Crizotinib in First-Line Treatment of ALK-Positive NSCLC?